Feed DNA
DN

Ginkgo Bioworks Holdings, Inc.

DNA · NYSE

$10.66 +4.00% (+$0.41)
1M +53.16%
Market Cap $670.6M
P/E Ratio -
Div. Yield -
ROE 60.21%

Bulios Fair Price

$5.8

45.6% downside

Trenutna cena

$10.66

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica DNA trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Weak
2/9
Valuation
62 /100
Fair
P/S 5.99x
P/B 1.60x
P/E N/A
Growth
0 /100
Declining
Rev. growth 29.11%
Book val. growth 33.59%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 80.09%
FCF margin 169.96%
Net margin 259.96%
Quality
1 /100
Poor
ROIC 31.63%
Asset turnover 0.11x
ROE 60.21%
Debt
68 /100
Low
Debt/Equity 0.96x
Current ratio 4.57x
Int. coverage N/A
Stability
52 /100
Moderate
Beta 1.77x
Profitable years 0
Rev. volatility 18.93%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o DNA
Online

O podjetju

Ginkgo Bioworks Holdings, Inc. (DNA) is a biotechnology company focused on synthetic biology and engineering microorganisms. The company uses advanced technologies and biological systems to create new organisms and biological functions for various applications. Ginkgo Bioworks specializes in genetic modification and design of microorganisms, enabling the production of novel drugs, biochemical substances, industrial products, and other biologically-based technologies. The company collaborates with various industries and pharmaceutical companies on the development of new products and innovations that can have a positive impact on the environment and human health. Ginkgo Bioworks Holdings, Inc. (DNA) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focused on innovation and the development of biological technologies with the potential for broader societal impact.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Jason Kelly

Employees

485

Headquarters

Boston

Prihajajoči dogodki

05 NOV.

Earnings

Upcoming earnings report

39d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.